[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.241.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1993

How Shall Research in the Treatment of Retinitis Pigmentosa Proceed?

Author Affiliations

Durham, NC

Arch Ophthalmol. 1993;111(6):754-756. doi:10.1001/archopht.1993.01090060042020

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

Retinitis pigmentosa (RP) is a group of hereditary eye diseases, characterized by retinal degeneration, that have no known cure.1 The prevalence of RP is approximately one in 3000 persons worldwide. The initial symptom of RP is night blindness that usually begins during adolescence. Patients next experience constricted visual fields and eventually a profound loss of peripheral vision. In the course of the eye's deteriorating condition, abnormal pigmentation characteristically accumulates, starting usually in the midperipheral retina. Typically by middle age, the patients are legally blind. The pattern of RP recurrence in an individual's family indicates whether the genetic type is X-linked, recessive, or dominant.1

Ideally, research in RP treatment should begin when all the variations on the pathogenic chain of events resulting in the phenotype have been identified. Although RP research has not arrived at this point, a considerable body of knowledge about some of the critical cellular and

References
1.
Heckenlively IR. Retinitis Pigmentosa . Philadelphia, Pa: JB Lippincott; 1988:14-24, 37-89.
2.
Humphries P, Kenna P, Farrar GJ.  On the molecular genetics of retinitis pigmentosa . Science . 1992;256:804-808.Article
3.
Stryer L.  Visual excitation and recovery . J Biol Chem . 1991;266:10711-10714.
4.
Gobind Khorana H.  Rhodopsin, photoreceptor of the rod cell: an emerging pattern for structure and function . J Biol Chem . 1992;267:1-4.
5.
Sanyal S, DeRuiter A, Hawkins RK.  Development and degeneration of retina in rds mutant mice: light microscopy . J Comp Neurol . 1980;194:193-198.Article
6.
Hawkins RK, Jansen HG, Sanyal S.  Development and degeneration of retina in rds mutant mice: photoreceptor abnormalities in the heterozygotes . Exp Eye Res . 1985;41:701-720.Article
7.
Connell G, Bascom R, Molday L, Reid D, McInnes RR, Molday RS.  Photoreceptor peripherin is the normal product of the gene responsible for retinal degeneration in the rds mouse . Proc Natl Acad Sci U S A . 1991;88:723-726.Article
8.
Travis GH, Sutcliffe JG, Bok D.  The retinal degeneration slow (rds) gene product is a photoreceptor disc membrane-associated glycoprotein . Neuron . 1991;6:61-70.Article
9.
Sanyal S, Jansen HG, Aguirre G, van Veen T, Broekhuyse RM, de Grip WJ.  Functional differentiation of outer segments and photoreceptor cell death in the retina of rds mutant mice . In: Anderson RE, Hollyfield JG, LaVail MM, eds. Retinal Degenerations . Boca Raton, Fla: CRC Press Inc; 1991:13-27.
10.
Hargrave PA, O'Brien PJ.  Speculations on the molecular basis of retinal degeneration in retinitis pigmentosa . In: Anderson RE, Hollyfield JG, LaVail MM, eds. Retinal Degenerations . Boca Raton, Fla: CRC Press Inc; 1991:517-528.
11.
Sung C-H, Schneider BG, Agarwal N, Papermaster DS, Nathans J.  Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa . Proc Natl Acad Sci U S A . 1991;88:8840-8844.Article
12.
Anderson WF.  Human gene therapy . Science . 1992;256:808-813.Article
13.
Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM.  Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor . Nature . 1990;347:83-86.Article
14.
Hewitt AT, Lindsey JD, Carbott D, Adler R.  Photoreceptor survival-promoting activity in interphotoreceptor matrix preparations: characterization and partial purification . Exp Eye Res . 1990;50:79-88.Article
15.
Bozyczko-Coyne C, Bacon R, Neff N.  Rod photoreceptor cell survival in vitro is supported by insulin-like growth factor-I . Invest Ophthalmol Vis Sci . 1992;33( (suppl) ):820.
16.
Chader GJ, Aguirre GD, Sanyal S.  Studies on animal models of retinal degeneration . In: Tso MOM, ed. Retinal Diseases:Biomedical Foundations and Clinical Management . Philadelphia, Pa: JB Lippincott; 1988:80-99.
17.
Olsson JE, Gordon JW, Pawlyk BS, Berson EL, Dryja TP.  Construction of transgenic mice that carry a mutant copy of the human rhodopsin gene (Pro23His) . Invest Ophthalmol Vis Sci . 1991;32( (suppl) ):782.
18.
Wong F, Hao Y.  Transgenic mouse model of retinal degeneration caused by mutations in proline 347 of rhodopsin . Invest Ophthalmol Vis Sci . 1992;33 ( (suppl) ):944.
19.
Olsson JE, Pawlyk BS, Gordon JW, Berson EL, Dryja TP.  Transgenic mice that carry a mutant copy of the human rhodopsin gene (Pro347Ser) . Invest Ophthalmol Vis Sci . 1992;33( (suppl) ):1398.
20.
Bowes C, Li T, Danciger M, Baxter LC, Applebury ML, Farber DB.  Retinal degeneration in the rd mouse is caused by a defect in the β subunit of rod cGMP-phosphodiesterase . Nature . 1990;347:677-680.Article
21.
La Vail MM, Unoki K, Yasumura D, Matthes MT, Yancopoulos GD, Steinberg RH.  Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light . Proc Natl Acad Sci USA . 1992;89:11249-11253.Article
22.
Berson EL, Rosner B, Sandberg MA, et al.  A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa . Arch Ophthalmol . 1993;111:761-772.Article
×